Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 2.95% on October 22, with a trading volume of 86.9732 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's total shares increased by 62 million, bringing the latest total to 1.052 billion shares [1] - The latest net asset value of the fund is calculated at 929 million yuan [1] - Since its inception on September 12, 2025, the fund has reported a return of -11.74%, while the return over the past month is -11.10% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - The performance benchmark for the fund is the National Index for Hong Kong Stock Connect Innovative Drugs, adjusted for valuation exchange rates [1]
10月22日港股通创新药ETF南方（159297）份额增加6200.00万份，最新份额10.52亿份，最新规模9.29亿元
Xin Lang Cai Jing·2025-10-23 04:54